Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
or

Structure Therapeutics Inc (GPCR)

Structure Therapeutics Inc (GPCR)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
19.77 -0.17 (-0.85%) 03/28/25 [NASDAQ]
N/A x N/A N/A x N/A
Post-market 19.77 unch (unch) 16:33 ET
Quote Overview for Fri, Mar 28th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
18.87
Day High
19.84
Open 19.75
Previous Close 19.94 19.94
Volume 448,300 448,300
Avg Vol 747,640 747,640
Stochastic %K 15.96% 15.96%
Weighted Alpha -65.75 -65.75
5-Day Change -1.20 (-5.72%) -1.20 (-5.72%)
52-Week Range 18.87 - 62.74 18.87 - 62.74
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,133,671
  • Shares Outstanding, K 57,343
  • Annual Sales, $ 0 K
  • Annual Income, $ -122,530 K
  • EBIT $ -158 M
  • EBITDA $ -176 M
  • 60-Month Beta -2.37
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.32

Options Overview Details

View History
  • Implied Volatility 79.01% ( +5.94%)
  • Historical Volatility 83.18%
  • IV Percentile 43%
  • IV Rank 12.51%
  • IV High 224.41% on 05/31/24
  • IV Low 58.22% on 08/23/24
  • Put/Call Vol Ratio 0.06
  • Today's Volume 166
  • Volume Avg (30-Day) 480
  • Put/Call OI Ratio 0.83
  • Today's Open Interest 17,019
  • Open Int (30-Day) 17,120

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.24
  • Number of Estimates 7
  • High Estimate -0.17
  • Low Estimate -0.31
  • Prior Year -0.19
  • Growth Rate Est. (year over year) -26.32%

Price Performance

See More
Period Period Low Period High Performance
1-Month
18.87 +4.77%
on 03/28/25
Period Open: 23.75
23.77 -16.83%
on 03/03/25
-3.98 (-16.76%)
since 02/28/25
3-Month
18.87 +4.77%
on 03/28/25
Period Open: 29.04
31.72 -37.67%
on 01/31/25
-9.27 (-31.92%)
since 12/27/24
52-Week
18.87 +4.77%
on 03/28/25
Period Open: 42.86
62.74 -68.49%
on 06/03/24
-23.09 (-53.87%)
since 03/28/24

Most Recent Stories

More News
The State of Weight Loss Drugs

In this podcast, Motley Fool analyst Karl Thiel joins host Ricky Mulvey to check in on the GLP-1 landscape. They discuss:

GIS : 59.11 (-0.92%)
VKTX : 25.65 (-1.84%)
NVO : 69.30 (-1.23%)
HIMS : 29.14 (-8.71%)
LLY : 822.51 (+0.10%)
CAG : 26.55 (+0.34%)
GPCR : 19.77 (-0.85%)
ISRG : 491.84 (-3.16%)
PFE : 25.21 (+0.80%)
Structure Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Highlights

GPCR : 19.77 (-0.85%)
Why Structure Therapeutics Stock Was Stumbling This Week

The past few days haven't been kind to most stocks in the white-hot obesity drugs space. One developer of a weight loss medication, clinical-stage biotech Structure Therapeutics (NASDAQ: GPCR), was a victim...

LLY : 822.51 (+0.10%)
GPCR : 19.77 (-0.85%)
Structure Therapeutics to Participate in Multiple Upcoming Healthcare Investor Conferences

GPCR : 19.77 (-0.85%)
AI Pharma: 2 Paths to AI-Powered Drug Investment

AI is transforming drug development, allowing companies to identify new drug targets, optimize clinical trials and speed delivery of medicines to patients.

LLY : 822.51 (+0.10%)
GPCR : 19.77 (-0.85%)
SDGR : 19.96 (-1.48%)
NVS : 112.57 (+1.05%)
RXRX : 5.81 (-2.68%)
Structure Therapeutics Inc. Advances ACCG-2671 as Lead Oral Amylin-Based Drug Candidate with Promising Preclinical Results

ACCG-2671 shows promise for weight loss and safety, with Phase 1 trials planned by late 2025.Quiver AI SummaryStructure Therapeutics Inc. has announced the selection of its lead oral small molecule amylin...

GPCR : 19.77 (-0.85%)
Structure Therapeutics Announces Selection of Lead Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity

GPCR : 19.77 (-0.85%)
2 ‘Monster’ Stocks to Snap Up Before 2025

Analysts at Jefferies have identified Metagenomi and Structure Therapeutics as two "monster" stocks in the biotech sector, with potential gains of up to 1,000%.

GPCR : 19.77 (-0.85%)
MGX : 1.4800 (-3.90%)
Structure Therapeutics to Participate in the Jefferies London Healthcare Conference

GPCR : 19.77 (-0.85%)
Structure Therapeutics Reports Third Quarter 2024 Financial Results and Recent Highlights

GPCR : 19.77 (-0.85%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Structure Therapeutics Inc. is a clinical-stage global biopharmaceutical company discovering and developing novel oral therapeutics to treat chronic metabolic and pulmonary diseases with unmet medical needs. Structure Therapeutics Inc. is based in SAN FRANCISCO.

See More

Key Turning Points

3rd Resistance Point 21.09
2nd Resistance Point 20.47
1st Resistance Point 20.12
Last Price 19.77
1st Support Level 19.15
2nd Support Level 18.52
3rd Support Level 18.17

See More

52-Week High 62.74
Fibonacci 61.8% 45.98
Fibonacci 50% 40.81
Fibonacci 38.2% 35.63
Last Price 19.77
52-Week Low 18.87

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Trading Volatility: How to Use IV Rank & Percentile for Smarter Options Strategies